Exact Sciences(US:EXAS)2025-02-19 23:28Financial Performance & Growth - Total revenue in 2024 reached $2.76 billion, a 10% year-over-year increase[6] - Adjusted EBITDA for 2024 was $323 million, up 48% year-over-year[6] - Core revenue grew by 11% in the fourth quarter of 2024[8] - Screening revenue in Q4 2024 increased to $553 million, a 14% increase compared to $487 million in Q4 2023[9] - Precision Oncology revenue in Q4 2024 increased to $161 million, a 0.4% increase compared to $160 million in Q4 2023[9] - Adjusted EBITDA margin improved to 11% in Q4 2024, compared to 8% in Q4 2023[12] - Free cash flow increased by 133% from $32 million in 2023 to $75 million in 2024[15] 2025 Guidance - The company projects total revenue between $3.025 billion and $3.085 billion for 2025, representing an 11% increase at the midpoint[17] - Screening revenue is expected to be between $2.350 billion and $2.390 billion, a 13% increase at the midpoint[17] - Precision Oncology revenue is projected to be between $675 million and $695 million, a 5% increase at the midpoint[17] - Adjusted EBITDA is guided to be between $410 million and $440 million, a 31% increase at the midpoint[17]